首页|富马酸伏诺拉生联合阿莫西林治疗幽门螺杆菌感染的临床效果

富马酸伏诺拉生联合阿莫西林治疗幽门螺杆菌感染的临床效果

扫码查看
目的 观察富马酸伏诺拉生联合阿莫西林治疗幽门螺杆菌感染的临床效果。方法 选取 2023 年1 月—2024 年1 月临沂市中心医院收治的幽门螺杆菌感染患者62 例,采用随机数字表法分为研究组和对照组,每组31 例。对照组采用常规四联疗法治疗,研究组采用富马酸伏诺拉生联合阿莫西林治疗,2 组均治疗1 个月。比较2 组临床疗效,治疗前后症状积分、炎性指标[白介素-2(IL-2)、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、C反应蛋白(CRP)]水平,幽门螺杆菌根除率、复发率及不良反应。结果 研究组总有效率(96。77%)高于对照组(80。65%)(χ2=4。026,P=0。045)。治疗1 个月后,2 组上腹痛、反酸嗳气、恶心呕吐积分均低于治疗前,且研究组低于对照组(P<0。05 或P<0。01);2 组IL-2、TNF-α、IL-6 及CRP水平均低于治疗前,且研究组低于对照组(P<0。01)。研究组幽门螺杆菌根除率为96。77%(30/31),高于对照组的80。65%(25/31)(χ2=4。026,P=0。045);研究组疾病复发率为3。33%(1/30),低于对照组的28。00%(7/25)(χ2=4。838,P=0。028)。研究组不良反应总发生率(3。23%)低于对照组(19。35%)(χ2=4。026,P=0。045)。结论 富马酸伏诺拉生联合阿莫西林治疗幽门螺杆菌感染的疗效较好,安全性较高,可改善患者症状,降低血清炎性指标,提升幽门螺杆菌根除率,降低疾病复发率。
Clinical effect of vonoprazan fumarate combined with amoxicillin in the treatment of Helicobacter pylori infection
Objective To observe the clinical effect of vonoprazan fumarate combined with amoxicillin in the treat-ment of Helicobacter pylori infection.Methods A total of 62 Helicobacter pylori infected patients admitted to Linyi Central Hospital from January 2023 to January 2024 were selected and divided into study group and control group by random number table method,with 31 cases in each group.The control group was treated with conventional quadruple therapy,and the study group was treated with vonoprazan fumarate combined with amoxicillin.Both groups were treated for 1 month.The clinical effi-cacy,symptom scores and inflammatory indexes(IL-2,TNF-α,IL-6,CRP)levels before and after treatment,eradication rate of Helicobacter pylori,recurrence rate and adverse reactions of two groups were compared.Results The total effective rate of the study group(96.77%)was higher than that of the control group(80.65%)(χ2=4.026,P=0.045).After 1 month of treatment,the scores of epigastric pain and regurgitation,nausea and vomiting in two groups were lower than before treatment,and those in the study group were lower than those in the control group(P<0.05 or P<0.01).The levels of IL-2,TNF-α,IL-6 and CRP in two groups were lower than before treatment,and the levels in study group were lower than those in control group(P<0.01).The eradication rate of Helicobacter pylori the research group was 96.77%,which was higher than that in the control group(80.65%)(χ2=4.026,P=0.045).The recurrence rate of the study group was 3.33%,which was lower than that of the control group(28.00%)(χ2=4.838,P=0.028).The total incidence of adverse reactions in the study group(3.23%)was lower than that in the control group(19.35%)(χ2=4.026,P=0.045).Conclusion The combination of vonoprazan fumarate and amoxicillin in the treatment of Helicobacter pylori infection has good efficacy and high safety,which can improve the symptoms of patients,reduce serum inflammatory indexes,increase the eradication rate of Helicobacter pylori,and reduce the recurrence rate of the disease.

Helicobacter pylori infectionVonoprazan fumarateAmoxicillinClinical effectSymptom scoresInflammatory indexHelicobacter pylori eradication rateAdverse reaction

武善霞、刘洋

展开 >

276400 山东省临沂市中心医院药学部

幽门螺杆菌感染 富马酸伏诺拉生 阿莫西林 临床疗效 症状积分 炎性指标 幽门螺杆菌根除率 不良反应

2025

临床合理用药
河北省科学技术协会

临床合理用药

影响因子:0.799
ISSN:1374-3296
年,卷(期):2025.18(2)